

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Information for the public

Published: 15 September 2021

www.nice.org.uk

Abemaciclib (Verzenios) plus fulvestrant is available on the NHS. It is a possible treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had endocrine therapy. It is only available if exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 inhibitor.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS website may be a good place to find out more about [breast cancer in women](#) and [breast cancer in men](#).

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0808 800 6000
- [Macmillan Cancer Support](#), 0808 808 0000
- [Cancer Research UK](#), 0808 800 4040

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4260-2